Funded Startups in Basel
Basel's funded startup ecosystem across these 34 rounds is heavily concentrated in biotechnology and health care — 29 of the 34 companies operate in one of…
Basel's funded startup ecosystem across these 34 rounds is heavily concentrated in biotechnology and health care — 29 of the 34 companies operate in one of those two sectors. The largest disclosed round is Noema Pharma's $147M Series B closed in December 2024, followed by VectivBio's $125M Post-IPO Equity in October 2022 and Bright Peak Therapeutics' $107M raise in June 2021.
Activity has continued into 2025, with Granite Bio securing a $70M Series B in April and Axmed closing $5M in May. Outside the life sciences, the dataset includes Azuro (real estate and lifestyle, $6M Seed, October 2025), Lyfegen (financial services, $6M Series A, December 2024), and Scailyte (AI, $2M Series A, December 2023), though these remain exceptions rather than a structural trend.
Most recent rounds
34 shownRelated listings
Frequently asked
What are the largest disclosed rounds from Basel startups in this dataset?
Noema Pharma leads at $147M (Series B, December 2024), followed by VectivBio at $125M (Post-IPO Equity, October 2022), Bright Peak Therapeutics at $107M (June 2021), Monte Rosa Therapeutics at $95M (Series C, March 2021), and Nouscom at $83M (March 2024). Granite Bio's $70M Series B in April 2025 is the largest round dated to 2025.
Which sectors dominate Basel's funded startup ecosystem?
Biotechnology accounts for 23 of the 34 companies in this dataset, with Health Care adding another 6. The remaining five span financial services, AI, real estate, agriculture, and professional services — present but not a structural pattern.
What round stages appear most often among Basel startups?
"Series Unknown" is the most frequently listed round type, appearing across nine companies including Axmed, BioVersys, Kinarus Therapeutics, and Bottneuro. Six additional companies — including Nouscom ($83M) and Arvelle Therapeutics ($43M) — have no round type listed at all. Series B rounds have produced the two largest fully-labeled amounts: $147M for Noema Pharma and $70M for Granite Bio.
How active has Basel's funding scene been in 2024 and 2025?
Twelve of the 34 rounds in this dataset are dated to 2024 or 2025. The four 2025 entries include Granite Bio's $70M Series B in April, Axmed's $5M in May, DropGen's $30K Pre-Seed in July, and Azuro's $6M Seed in October. The eight 2024 rounds include Noema Pharma's $147M Series B and Lyfegen's $6M Series A, both closed in December 2024.
Are there Basel startups outside biotechnology and health care raising rounds?
Yes, though they are a small minority. Azuro (real estate and lifestyle) raised $6M in a Seed round in October 2025; Lyfegen (financial services) raised $6M in a Series A in December 2024; Scailyte (AI) raised $2M in a Series A in December 2023; Kidemis (agriculture) raised $160K in April 2024; and BioTara (professional services) closed an undisclosed round in September 2024.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.